|
Post by sayhey24 on Aug 3, 2017 19:51:50 GMT -5
Wow - now this is an amazing thread based on "Cash flow problem? No problem. My guess is there will be an announcement of a 100,000,000 new share offering at $1.00/shr with rights" Clearly, based on approved shares this is not possible by Monday. But it does raise an interesting question - Why would anyone provide $100M to a company which has a failed product which has a history of few to "almost no" sales? Nobody in their right mind would give them $100M unless of course they had a really really good reason. And, if so they would probably want at least a 10x return on the money. What could someone be thinking or someone know that MNKD in 5yrs or less would be worth $10 pps based on a $100M cash infusion? What would they use the money for with a "failed" product, more sales people, more mystery business relationships, more TV show sponsoring? How is that ever going to help a failed product which no one wants and no doctor will ever prescribe? That's what they keep telling us, right? If we can get the sales after the $100M infusion, why can't we get the sales now and skip the dilution? I know its a crazy idea but I keep seeing things like the VDex paper and Edelman at BeyondA1c diatribe.org/the-diatribe-foundation-and-tcoyd-11th-annual-forum afrezza just seems like a damn good product which is better than anything else according to VDex and everyone else who has used it. Guys like Edelman uses it himself. To quote Dr. Ralph DeFronzo from the University of Texas Health Science Center at the BeyondA1c Forum - "“The most waste in type 2 diabetes is to continuously put people on metformin and sulfonylureas (glyburide, glimepiride, etc.). These drugs have no protective effect on the beta cell, and by the time you figure out what you’re doing, there are no beta cells left to save.” It seems he was listening to Dr. Edleman's presentation. Hopefully Mike can close some big deals really soon and we can start seeing some quarter over quarter huge gains.
|
|
|
Post by dreamboatcruise on Aug 3, 2017 20:02:06 GMT -5
Wow - now this is an amazing thread based on "Cash flow problem? No problem. My guess is there will be an announcement of a 100,000,000 new share offering at $1.00/shr with rights" Clearly, based on approved shares this is not possible by Monday. But it does raise an interesting question - Why would anyone provide $100M to a company which has a failed product which has a history of few to "almost no" sales? Nobody in their right mind would give them $100M unless of course they had a really really good reason. And, if so they would probably want at least a 10x return on the money. What could someone be thinking or someone know that MNKD in 5yrs or less would be worth $10 pps based on a $100M cash infusion? What would they use the money for with a "failed" product, more sales people, more mystery business relationships, more TV show sponsoring? How is that ever going to help a failed product which no one wants and no doctor will ever prescribe? That's what they keep telling us, right? If we can get the sales after the $100M infusion, why can't we get the sales now and skip the dilution? I know its a crazy idea but I keep seeing things like the VDex paper and Edelman at BeyondA1c diatribe.org/the-diatribe-foundation-and-tcoyd-11th-annual-forum afrezza just seems like a damn good product which is better than anything else according to VDex and everyone else who has used it. Guys like Edelman uses it himself. To quote Dr. Ralph DeFronzo from the University of Texas Health Science Center at the BeyondA1c Forum - "“The most waste in type 2 diabetes is to continuously put people on metformin and sulfonylureas (glyburide, glimepiride, etc.). These drugs have no protective effect on the beta cell, and by the time you figure out what you’re doing, there are no beta cells left to save.” It seems he was listening to Dr. Edleman's presentation. Hopefully Mike can close some big deals really soon and we can start seeing some quarter over quarter huge gains. By when are you guessing this 100M share offer will occur so we can grade your guessing abilities? I would certainly bet against that happening as the next significant financial event.
|
|
|
Post by sayhey24 on Aug 3, 2017 20:17:41 GMT -5
I would say never. No one in their right mind would give a failing company with a failed product any more money. I think they call that insanity. Then again if they have as good a product as people are now saying they won't need dilution, a bridge loan will do just fine. Lets see on Monday what Mike has been doing for the last 20 months.
|
|
|
Post by mbseeking on Aug 3, 2017 20:26:41 GMT -5
So debt is out. Matt I appreciate your clarity. So equity is only solution. But equity seems out because there are not enough shares to issue or time to issue new ones before the cash runs out. Also convertible debt seems not doable as the shares aren't yet issued to cover it ...
And we're the supporters of MNKD?
Could we have fallen into an intelligence trap?
I can see at least one viable path.. you correct me if I'm wrong. it assumes management have found an equity partner for , say $100M... Simultaneously announce the convertible offering.. together with the shareholder meeting on additional share issuance.. Both of these could then happen before, just before MNKD runs out of doh. All above board.. the shareholders could refuse to issue.. claim a gun to their head, but I doubt it. Everything would be visible , doubt Nasdaq would have any issue.
Ok.. and a partner.. well its only adding to speculation.. but I can't help notice that Binder just finished a stint in Singapore.. a country madly obsessive about getting a pharma industry up and running. So for partner like Temasek comes to mind.. as just one example..
Normally the moderators would call this speculation and frown on this post. But today I lay it out in the hope that you realise you may have fallen into the depression of an intelligence trap. There is not much, but there is still hope for MNKD/Afrezza.
|
|
|
Post by dreamboatcruise on Aug 3, 2017 20:29:16 GMT -5
I would say never. No one in their right mind would give a failing company with a failed product any more money. I think they call that insanity. Then again if they have as good a product as people are now saying they won't need dilution, a bridge loan will do just fine. Lets see on Monday what Mike has been doing for the last 20 months. I tend to think management to be an honest bunch. Until proven guilty of hiding things from shareholders I'll assume MNKD's been doing what we've been told it was doing for the last 20 months. So you're predicting a bridge loan? By when and how much?
|
|
|
Post by brotherm1 on Aug 3, 2017 20:49:47 GMT -5
I believe he said let's see what happens Monday.
|
|
|
Post by sayhey24 on Aug 3, 2017 20:52:36 GMT -5
I would say never. No one in their right mind would give a failing company with a failed product any more money. I think they call that insanity. Then again if they have as good a product as people are now saying they won't need dilution, a bridge loan will do just fine. Lets see on Monday what Mike has been doing for the last 20 months. I tend to think management to be an honest bunch. Until proven guilty of hiding things from shareholders I'll assume MNKD's been doing what we've been told it was doing for the last 20 months. So you're predicting a bridge loan? By when and how much? I think Mike is going to close some big distributorships with guaranteed sales. Call me crazy. You would not be the first. I have been saying how great afrezza is for years and for years I have been laughed at and mocked. Finally things are starting to turn. I told Mike at last years ASM afrezza was doomed and the only thing which would save it was technology - CGMs and cloud monitoring. Do you know how great it was to read the VDex report and see them saying what I have been laughed at for years? Guys like Scheiner who would never touch afrezza three years ago are now using it himself. The big take away from ADA 2017 conference was time in range with CGMs /Monitoring and a good part of the BeyondA1c Forum was about afrezza. The cherry on top is the good doctor from Texas finally calling out the use of metformin and the other T2 meds as insanity. Since ADA 2017 afrezza has been living rent free in the heads of every BP president. All of BP was at the BeyondA1c Forum and heard Edelman go on and on about amazing patient results. My money is on Mike closing some deals. Maybe I am wrong but I don't think I am. What was Apple down to at one point, less than 90 days only to be saved by Bill Gates. Maybe Gates wants to get into diabetes now, or Apple or Google, maybe even IBM Watson. Closing some sales while having Tim Cook hanging around would be OK by me.
|
|
|
Post by n8 on Aug 3, 2017 20:53:02 GMT -5
I would say never. No one in their right mind would give a failing company with a failed product any more money. I think they call that insanity. Then again if they have as good a product as people are now saying they won't need dilution, a bridge loan will do just fine. Lets see on Monday what Mike has been doing for the last 20 months. I tend to think management to be an honest bunch. Until proven guilty of hiding things from shareholders I'll assume MNKD's been doing what we've been told it was doing for the last 20 months. So you're predicting a bridge loan? By when and how much? Confidentiality agreements?
|
|
|
Post by straightly on Aug 3, 2017 20:55:27 GMT -5
Wow - now this is an amazing thread based on "Cash flow problem? No problem. My guess is there will be an announcement of a 100,000,000 new share offering at $1.00/shr with rights" Clearly, based on approved shares this is not possible by Monday. But it does raise an interesting question - Why would anyone provide $100M to a company which has a failed product which has a history of few to "almost no" sales? Nobody in their right mind would give them $100M unless of course they had a really really good reason. And, if so they would probably want at least a 10x return on the money. What could someone be thinking or someone know that MNKD in 5yrs or less would be worth $10 pps based on a $100M cash infusion? What would they use the money for with a "failed" product, more sales people, more mystery business relationships, more TV show sponsoring? How is that ever going to help a failed product which no one wants and no doctor will ever prescribe? That's what they keep telling us, right? If we can get the sales after the $100M infusion, why can't we get the sales now and skip the dilution? I know its a crazy idea but I keep seeing things like the VDex paper and Edelman at BeyondA1c diatribe.org/the-diatribe-foundation-and-tcoyd-11th-annual-forum afrezza just seems like a damn good product which is better than anything else according to VDex and everyone else who has used it. Guys like Edelman uses it himself. To quote Dr. Ralph DeFronzo from the University of Texas Health Science Center at the BeyondA1c Forum - "“The most waste in type 2 diabetes is to continuously put people on metformin and sulfonylureas (glyburide, glimepiride, etc.). These drugs have no protective effect on the beta cell, and by the time you figure out what you’re doing, there are no beta cells left to save.” It seems he was listening to Dr. Edleman's presentation. Hopefully Mike can close some big deals really soon and we can start seeing some quarter over quarter huge gains. If I had $100m and hell bent on investing in MNKD, which will be my best choice? 1. Buy stocks on the open market, squeeze the daylight out of the shorts. 2. Loan the money to MNKD with very favorable terms. 3. Buy new shares from MNKD. 4. Wait for my chance for a chance in the bankruptcy court. We of course already know the answer. But do you know why?
|
|
|
Post by agedhippie on Aug 3, 2017 21:08:48 GMT -5
Wow - now this is an amazing thread based on "Cash flow problem? No problem. My guess is there will be an announcement of a 100,000,000 new share offering at $1.00/shr with rights" Clearly, based on approved shares this is not possible by Monday. But it does raise an interesting question - Why would anyone provide $100M to a company which has a failed product which has a history of few to "almost no" sales? Nobody in their right mind would give them $100M unless of course they had a really really good reason. And, if so they would probably want at least a 10x return on the money. What could someone be thinking or someone know that MNKD in 5yrs or less would be worth $10 pps based on a $100M cash infusion? What would they use the money for with a "failed" product, more sales people, more mystery business relationships, more TV show sponsoring? How is that ever going to help a failed product which no one wants and no doctor will ever prescribe? That's what they keep telling us, right? If we can get the sales after the $100M infusion, why can't we get the sales now and skip the dilution? I know its a crazy idea but I keep seeing things like the VDex paper and Edelman at BeyondA1c diatribe.org/the-diatribe-foundation-and-tcoyd-11th-annual-forum afrezza just seems like a damn good product which is better than anything else according to VDex and everyone else who has used it. Guys like Edelman uses it himself. To quote Dr. Ralph DeFronzo from the University of Texas Health Science Center at the BeyondA1c Forum - "“The most waste in type 2 diabetes is to continuously put people on metformin and sulfonylureas (glyburide, glimepiride, etc.). These drugs have no protective effect on the beta cell, and by the time you figure out what you’re doing, there are no beta cells left to save.” It seems he was listening to Dr. Edleman's presentation. Hopefully Mike can close some big deals really soon and we can start seeing some quarter over quarter huge gains. If I had $100m and hell bent on investing in MNKD, which will be my best choice? 1. Buy stocks on the open market, squeeze the daylight out of the shorts. 2. Loan the money to MNKD with very favorable terms. 3. Buy new shares from MNKD. 4. Wait for my chance for a chance in the bankruptcy court. We of course already know the answer. But do you know why? Lets look at them: 1. Cannot be done, the share count is to small, it would require you to buy the company. 2. This would work but it would be an unsecured loan since Deerfield already have first rights to the assets. You may as well donate the money to MNKD. 3. Could be done, but Mannkind are not about to do this for the reasons I outlined earlier 4. This too would work but who knows if you would get it or if someone else would win. High risk. If you had $100 million the way to do it would be to leach it in in small regular tranches of maybe $10 million. The market could absorb that, and if Mannkind fell apart you could stop the payments to limit any loss.
|
|
|
Post by helmut8056 on Aug 3, 2017 22:06:24 GMT -5
My obit: I did nothing in particular, but I did it very well. -- Gilbert & Sullivan
|
|
Tinkerbell
Researcher
Watcher of the Skies
Posts: 143
|
Post by Tinkerbell on Aug 3, 2017 22:31:27 GMT -5
If I had $100m and hell bent on investing in MNKD, which will be my best choice? 1. Buy stocks on the open market, squeeze the daylight out of the shorts. 2. Loan the money to MNKD with very favorable terms. 3. Buy new shares from MNKD. 4. Wait for my chance for a chance in the bankruptcy court. We of course already know the answer. But do you know why? Lets look at them: 1. Cannot be done, the share count is to small, it would require you to buy the company. 2. This would work but it would be an unsecured loan since Deerfield already have first rights to the assets. You may as well donate the money to MNKD. 3. Could be done, but Mannkind are not about to do this for the reasons I outlined earlier 4. This too would work but who knows if you would get it or if someone else would win. High risk. If you had $100 million the way to do it would be to leach it in in small regular tranches of maybe $10 million. The market could absorb that, and if Mannkind fell apart you could stop the payments to limit any loss. All, don't forget number 5 to the list above. .5 A friendly Reverse Merger with a private company (Receptor Life Sciences, Inc.) who by the way just secured their registration on July 29th (FINALLY) following almost 1 & 1/2 years of back and forth with the US Patent and Trademark office. Why so long? Because another business in MN had the name Receptors LLC (which is now classified as 'abandoned). There's been no business conducted under that name for the last 3 years therefore, it's has officially been rewarded to RLS inc. A friendly RS remains on the table too but again, this is also speculative.
|
|
|
Post by reality on Aug 3, 2017 23:43:49 GMT -5
5. seems more probable in light of Mango's great find?!
|
|
|
Post by babaoriley on Aug 4, 2017 0:47:33 GMT -5
I would say never. No one in their right mind would give a failing company with a failed product any more money. I think they call that insanity. Then again if they have as good a product as people are now saying they won't need dilution, a bridge loan will do just fine. Lets see on Monday what Mike has been doing for the last 20 months.I'm pretty sure part of that 20 months was used up in getting Matt out. Hope Mike was correct in assuming he (Mike) was the right guy to lead the company out of the mess the Sanofi CEO switch go us into.
|
|
|
Post by mytakeonit on Aug 4, 2017 1:53:49 GMT -5
|
|